Osteosarcoma, pediatric

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

Section editor
Unfilled
If you are interested in this role, please contact us at [email protected].
0 regimens on this page
0 variants on this page


This page contains studies that were specific to pediatric populations. For the more general osteosarcoma page, follow this link.

All lines of therapy

MAP [COG AOST0331]

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Marina et al. 2016 (EURAMOS-1 poor response) 2005-2011 Phase 3 (C) MAPIE Did not meet primary endpoint of EFS

Neoadjuvant therapy

Received by all patients and consists of 2 cycles of MAP.

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 1, 6
  • Doxorubicin (Adriamycin) 37.5 mg/m2 (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 1, 6
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 4, 5, 9, 10
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM

10 Week course


Adjuvant therapy

MAP Cycles 3-4: Good Responders and Poor Responders

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 12, 17
  • Doxorubicin (Adriamycin) 37.5 mg/m2 (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 12, 17
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 15, 16, 20, 21
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM

10 Week course


Consolidation

MAP Cycles 5-6: Good Responders and Poor Responders

Chemotherapy

  • Doxorubicin (Adriamycin) as follows:
    • Weeks 22 & 26: 37.5 mg/m2/day IV continuous infusion over 48 hours, started on day 1 (total dose per infusion: 75 mg/m2)
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 24, 25, 28, 29
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM

10 Week course

References

  1. EURAMOS-1 good response: Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, Krailo MD, Gebhardt M, Pápai Z, Meyer J, Nadel H, Randall RL, Deffenbaugh C, Nagarajan R, Brennan B, Letson GD, Teot LA, Goorin A, Baumhoer D, Kager L, Werner M, Lau CC, Sundby Hall K, Gelderblom H, Meyers P, Gorlick R, Windhager R, Helmke K, Eriksson M, Hoogerbrugge PM, Schomberg P, Tunn PU, Kühne T, Jürgens H, van den Berg H, Böhling T, Picton S, Renard M, Reichardt P, Gerss J, Butterfass-Bahloul T, Morris C, Hogendoorn PC, Seddon B, Calaminus G, Michelagnoli M, Dhooge C, Sydes MR, Bernstein M; EURAMOS-1 investigators. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative map: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015 Jul 10;33(20):2279-87. Epub 2015 Jun 1. link to original article link to PMC article PubMed
  2. EURAMOS-1 poor response: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. Epub 2016 Aug 25. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00134030

Relapsed Refractory

Retrieved from "https://hemonc.org/w/index.php?title=Osteosarcoma,_pediatric&oldid=78545"